tiprankstipranks
Advertisement
Advertisement

DYN Stock Latest News

Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data
RatingsBuy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data
18d ago
DYN
Dyne Therapeutics announces data from Phase 1/2 Deliver trial of z-rostudirsen
PremiumThe Fly
Dyne Therapeutics announces data from Phase 1/2 Deliver trial of z-rostudirsen
18d ago
DYN
Dyne Therapeutics initiates Phase 3 Harmonia trial of Z-Basivarsen in DM1
PremiumThe Fly
Dyne Therapeutics initiates Phase 3 Harmonia trial of Z-Basivarsen in DM1
18d ago
DYN
Controversial Prasad leaving FDA, NYT reports
PremiumThe Fly
Controversial Prasad leaving FDA, NYT reports
19d ago
AZN
BMY
Dyne Therapeutics price target lowered to $47 from $50 at Morgan Stanley
PremiumThe Fly
Dyne Therapeutics price target lowered to $47 from $50 at Morgan Stanley
24d ago
DYN
Dyne Therapeutics price target lowered to $50 from $60 at H.C. Wainwright
PremiumThe FlyDyne Therapeutics price target lowered to $50 from $60 at H.C. Wainwright
24d ago
DYN
Dyne Therapeutics reports Q4 EPS (76c), consensus (76c)
Premium
The Fly
Dyne Therapeutics reports Q4 EPS (76c), consensus (76c)
25d ago
DYN
Dyne Therapeutics announces upcoming presentations at MDA Conference
Premium
The Fly
Dyne Therapeutics announces upcoming presentations at MDA Conference
1M ago
DYN
Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen
PremiumThe Fly
Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen
2M ago
DYN
Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference
PremiumCompany Announcements
Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference
2M ago
8K
DYN
Dyne Therapeutics Appoints Vikram Karnani to Board
PremiumCompany Announcements
Dyne Therapeutics Appoints Vikram Karnani to Board
3M ago
8K
DYN
Dyne Therapeutics appoints Vikram Karnani to board of directors
PremiumThe Fly
Dyne Therapeutics appoints Vikram Karnani to board of directors
3M ago
DYN
COLL
Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI
PremiumThe FlyDyne Therapeutics price target lowered to $36 from $38 at Evercore ISI
3M ago
DYN
Dyne Therapeutics price target raised to $39 from $36 at Stifel
Premium
The Fly
Dyne Therapeutics price target raised to $39 from $36 at Stifel
4M ago
DYN
Dyne Therapeutics Announces Upsized Public Offering
Premium
Company Announcements
Dyne Therapeutics Announces Upsized Public Offering
4M ago
8K
DYN
Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
4M ago
M
NE
Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40
PremiumThe Fly
Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40
4M ago
DYN
Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer
PremiumThe Fly
Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer
4M ago
DYN
Dyne Therapeutics 18.98M share Secondary priced at $18.44
PremiumThe Fly
Dyne Therapeutics 18.98M share Secondary priced at $18.44
4M ago
DYN
Midday Fly By: Nvidia can ship H200s to China, Campbell’s reports Q1 beat
PremiumThe FlyMidday Fly By: Nvidia can ship H200s to China, Campbell’s reports Q1 beat
4M ago
C
F
Dyne Therapeutics falls -13.7%
Premium
The Fly
Dyne Therapeutics falls -13.7%
4M ago
DYN
Dyne Therapeutics falls -13.7%
Premium
The Fly
Dyne Therapeutics falls -13.7%
4M ago
DYN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >